ZMPSTE24 and Hutchinson-Gilford progeria syndrome: Two years ago, lonafarnib achieved a clinical approval in the US for the sake of reduction the risk of mortality in HGPS and for the medication of progeroid laminopathies, which are with the heterozygous Lamin A gene mutants or homozygous or compound heterozygous mutations of ZMPSTE24 [53,54].